Completed PHASE2 INTERVENTIONAL 2-arm NCT01480596

The Evaluation of Belimumab in Myasthenia Gravis (MG)

A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects With Generalized Myasthenia Gravis (MG)

Sponsor: GlaxoSmithKline

Conditions Myasthaenia Gravis

Interventions Belimumab Placebo

Updated 7 times since 2017 Last updated: Dec 15, 2016 Started: Apr 30, 2013 Primary completion: Aug 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Myasthaenia Gravis and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Burlington, United States , Chapel Hill, United States , Charleston, United States , Charlottesville, United States , Cologne, Germany , Colorado Springs, United States , Columbus, United States , Edmonton, Canada , Hershey, United States and 15 more locations